Maze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week Low – Should You Sell?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) reached a new 52-week low during trading on Monday . The stock traded as low as $9.88 and last traded at $11.49, with a volume of 13183 shares. The stock had previously closed at $10.99.

Analyst Upgrades and Downgrades

MAZE has been the topic of several recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price target on the stock. Leerink Partnrs raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Leerink Partners began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 target price on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Finally, Guggenheim began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 target price on the stock. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Price Performance

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.